

The Base Prospectus (as defined below) expires on 20 June 2026. On or prior to this date, a succeeding base prospectus (the "**2026 Base Prospectus**") will be published on the website of the Luxembourg Stock Exchange (www.LuxSE.com) and on the website of Leonteq Securities, AG (www.leonteq.com). Thereafter, the offering of the Products will continue under the 2026 Base Prospectus. The terms and conditions (and form of final terms) from the Base Prospectus will be incorporated by reference into the 2026 Base Prospectus and will continue to apply to the Products.

FINAL TERMS dated 25/02/2026



LEONTEQ SECURITIES AG

(incorporated in Switzerland)

acting through its Guernsey branch (Leonteq Securities AG, Guernsey Branch)

EUR 10'000'000 Outperformance Products with Participation due 27/03/2029 under the European Issuance and Offering Programme (the "Notes" or the "Products")

Issue Price: 96.50 per cent of the Specified Denomination

ISIN: CH1484581991

This document constitutes the final terms of the Products (the "**Final Terms**") described herein for the purposes of Article 6(3) of the EU Prospectus Regulation and is prepared in connection with the European Issuance and Offering Programme (the "**Programme**") established by Leonteq Securities AG which may also be acting through its Guernsey branch (Leonteq Securities AG, Guernsey Branch) or its Amsterdam branch (Leonteq Securities AG, Amsterdam Branch) (the "**Issuer**"). These Final Terms complete and should be read in conjunction with the Base Prospectus dated 20 June 2025 (the "**Base Prospectus**"), which constitutes a base prospectus for the purposes of the EU Prospectus Regulation. Full information on the Issuer and the offer of the Products is only available on the basis of the combination of these Final Terms and the Base Prospectus. A summary of the individual issue of the Products is annexed to these Final Terms.

The Products documented in these Final Terms may be considered structured products in Switzerland pursuant to Article 70 of the Swiss Financial Services Act ("**FinSA**") and are not subject to supervision by the Swiss Financial Market Supervisory Authority ("**FINMA**"). None of the Products constitute a participation in a collective investment scheme within the meaning of the Collective Investment Schemes Act ("**CISA**") and are neither subject to the authorisation nor the supervision by the FINMA and investors do not benefit from the specific investor protection provided under the CISA. Investors bear the credit risk of the Issuer.

The Base Prospectus, and any supplements thereto, are available for viewing at https://structuredproducts-ch.leonteq.com/services/prospectuses?language_id=1. Terms used herein shall have the same meaning as in the General Conditions, the Payout Conditions and the applicable Underlying Specific Conditions (as may be amended and/or supplemented up to, and including, 27.03.2026) set forth in the Base Prospectus.

PART A - OPERATIONAL INFORMATION

- | | | |
|----|-------------------------------------|-------------------------------------|
| 1. | Security Codes | |
| | ISIN: | CH1484581991 |
| | Common Code: | Not Applicable |
| | WKN: | Not Applicable |
| | Swiss Security Number: | 148458199 |
| | Other Identifier: | Not Applicable |
| 2. | Relevant Clearing System(s): | SIX SIS Ltd, Euroclear, Clearstream |
| 3. | Delivery: | Delivery against payment |
| 4. | Authorised Participant: | Not Applicable |

PART B – CONTRACTUAL TERMS

Provisions relating to the Products

- | | | |
|----|--------------------------------------|----------------|
| 5. | (a) Series: | Not Applicable |
| | (b) Tranche: | Not Applicable |
| 6. | Settlement Currency: | Euro ("EUR") |
| 7. | Products: | Notes |
| 8. | Notes: | Applicable |
| | (a) Issue Size as at the Issue Date: | EUR 10'000'000 |
| | (i) Tranche: | Not Applicable |
| | (ii) Series: | Not Applicable |
| | (b) Specified Denomination: | EUR 1'000 |
| | (c) Minimum Tradable Lot: | EUR 1'000 |
| 9. | Certificates: | Not Applicable |

10.	Calculation Amount:	EUR 1'000
11.	Issue Price:	96.50 per cent of the Specified Denomination (no distribution fees)
12.	Issue Date:	27/03/2026
13.	Redemption Date:	27/03/2029
14.	TCM Secured Product:	Applicable
	Current Value Calculation Agent Method:	Not Applicable
15.	Interest Record Date:	Not Applicable
16.	FX Disruption Event:	Applicable
	Specified Currency:	Not Applicable
17.	CNY FX Disruption Event:	Not Applicable
18.	Unwind Costs:	Not Applicable
19.	Settlement Expenses:	Not Applicable
20.	US Tax Selling Restriction:	Not Applicable
21.	Section 871(m) Withholding Tax:	The Issuer has determined (without regard to any other transactions) that payments on the Products should not be subject to US withholding tax under 871(m) of the Code.

Provisions relating to Payouts

22.	Coupon Provisions:	Not Applicable
23.	Autocall Provisions:	Not Applicable
24.	Issuer Call Option Provisions:	Not Applicable
25.	Investor Put Option Provisions:	Not Applicable
26.	Partial Redemption:	Not Applicable
27.	Payout Style:	Outperformance Product

28.	Yield Enhancement Products:	Not Applicable
29.	Twin Win Products:	Not Applicable
30.	Fixed Redemption Products:	Not Applicable
31.	Protection Products:	Not Applicable
32.	Bonus Products:	Not Applicable
33.	Reverse Convertible Products:	Not Applicable
34.	Barrier Reverse Convertible Products:	Not Applicable
35.	Tracker Products:	Not Applicable
36.	Dual Currency Products:	Not Applicable
37.	Discount Products:	Not Applicable
38.	Leverage Products:	Not Applicable
39.	Outperformance Products:	Applicable
	(a) Outperformance Product Style:	Outperformance with Participation
	(b) Product Direction:	Bullish
	(c) Underlying Valuation Dates - Adjustments for Scheduled Trading Days:	Single Underlying - as specified in the definition of the relevant Underlying Valuation Date
	(d) Underlying Valuation Dates - Adjustments for Disrupted Days:	Single Underlying - as described in the relevant Underlying Specific Conditions
	(e) Number of Underlying Components:	Not Applicable
	(f) Redemption Provisions:	Applicable
	(i) Strike Event:	Final Fixing Level is at or above its Strike Barrier Level
	- Strike Percentage:	Not Applicable
	(ii) Strike Barrier Level:	Initial Fixing Level
	(iii) Strike Level:	Not Applicable
	(iv) Strike Basket Level:	Not Applicable
	(v) Final Redemption Event:	Not Applicable

- (vi) Protection Percentage: 100.00 per cent.
 - (vii) Upside Participation Percentage: 200.00 per cent.
 - (viii) Downside Participation: Not Applicable
 - (ix) Upside Cap: Not Applicable
 - (x) Final Performance: Final Fixing Level/Initial Fixing Level
 - (xi) Final Return: (Final Fixing Level – Initial Fixing Level)/Initial Fixing Level
 - (xii) Final Redemption Cap: Not Applicable
 - (xiii) Initial Fixing Basket Level: Not Applicable
 - (xiv) Inverse Percentage (Final Performance): Not Applicable
 - (xv) Inverse Percentage (Final Return): Not Applicable
 - (g) Delivery and Residual Cash Settlement Provisions: Not Applicable - the Settlement Type is Cash Settlement
40. **Long-Short Products:** Not Applicable
41. **Dispersion Products:** Not Applicable
42. **Steeper Product:** Not Applicable

Provisions relating to the Underlying(s)

Underlying Table				
(i)	Underlyings	Bloomberg Code	Index Sponsor(s)	Initial Fixing Level (100.00%)
1	Leonteq European Defense 12%RC Index	LEONED12	Leonteq Securities AG	will be determined on the Initial Fixing Date

43. **Share Linked Conditions:** Not Applicable
44. **Participation Certificate (*Genussscheine*) Linked Conditions:** Not Applicable
45. **Index Linked Conditions:** Proprietary Index
- (a) Indices: Each index set forth in the Underlying Table above in the column entitled 'Underlying(s)'
 - (b) Underlying Currency: In respect of Leonteq European Defense 12%RC Index, EUR
 - (c) Index sponsor(s): As set forth in the Underlying Table above in the column entitled 'Index Sponsor(s)' in the row

		corresponding to the relevant Index
(d)	Additional Disruption Event(s):	In respect of each Index
	(i) Change in Law:	Applicable
	(ii) Hedging Disruption:	Applicable
	(iii) Increased Cost of Hedging:	Applicable
(e)	Maximum Days of Disruption:	Eight Scheduled Trading Days as specified in Index Linked Conditions 5 (Definitions)
(f)	Initial Fixing Date:	In respect of each Index, 20/03/2026
(g)	Initial Fixing Level:	In respect of Leonteq European Defense 12%RC Index, the Closing Index Level on the Initial Fixing Date for such Index
(h)	Final Fixing Date:	In respect of each Index 20/03/2029
(i)	Final Fixing Level:	In respect of Leonteq European Defense 12%RC Index, the Closing Index Level on the Final Fixing Date for such Index
46.	Depository Receipt Linked Conditions:	Not Applicable
47.	Commodity Linked Conditions:	Not Applicable
48.	Currency Exchange Rate Linked Conditions:	Not Applicable
49.	Futures Contract Linked Conditions:	Not Applicable
50.	Fixed Income Instrument and Derivative Instrument Linked Conditions:	Not Applicable
51.	ETF Linked Conditions:	Not Applicable
52.	Fund Linked Conditions:	Not Applicable
53.	Reference Rate Linked Conditions:	Not Applicable

General Provisions

54.	Form of Products:	SIX SIS Securities issued in uncertificated form in accordance with article 973c of the Swiss Code of Obligations
-----	--------------------------	---

55.	Prohibition of Sales to EEA Retail Investors:	Not Applicable
56.	Prohibition of Sales to UK Retail Investors:	Applicable
57.	Business Centre(s):	Zurich, T2
58.	Business Day Convention:	Following
59.	Specified Number of Business Days:	Eight
60.	Other Rounding Conventions:	Not Applicable
61.	Calculation Agent:	Leonteq Securities AG
62.	Paying Agent:	Leonteq Securities AG
63.	Additional Agents:	Not Applicable
64.	Notice Website:	www.leonteq.com
65.	Name(s) and address(es) of Lead Manager:	Leonteq Securities AG, Europaallee 39, 8004 Zurich, Switzerland
66.	Governing Law:	Swiss law

PART C - OTHER INFORMATION

1. **LISTING AND ADMISSION TO TRADING**
 - (a) Listing and Admission to Trading: Not Applicable
 - (b) Estimate of total expenses related to admission to trading: Not Applicable
2. **INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE OFFER**
Not Applicable
3. **REASONS FOR THE OFFER, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES**
 - (a) Reasons for the offer: General funding
 - (b) Estimated net proceeds: 100 per cent. of the Issue Size
 - (c) Estimated total expenses: Not Applicable - there are no estimated expenses charged to the Investor by the Issuer

4. **PERFORMANCE OF UNDERLYINGS, AND OTHER INFORMATION CONCERNING THE UNDERLYINGS**

Information about the past and future performance and volatility of Leonteq European Defense 12%RC Index can be found free of charge at <https://indices.leonteq.com> (but the information appearing on such website does not form part of these Final Terms).

5. **TERMS AND CONDITIONS OF THE OFFER**

5.1. **Authorised Offer(s)**

- | | |
|---|--|
| (a) Public Offer: | An offer of the Products may be made, subject to the conditions set out below by the Authorised Offeror(s) (specified in (b) immediately below) other than pursuant to Article 1(4) of the Prospectus Regulation in the Public Offer Jurisdiction(s) (specified in (c) immediately below) during the Offer Period (specified in (d) immediately below) subject to the conditions set out in the Base Prospectus and in (e) immediately below |
| (b) Name(s) and address(es), to the extent known to the Issuer, of the places in the various countries where the offer takes place (together the " Authorised Offeror(s) "): | Each financial intermediary specified in (i) and (ii) below:
(i) Specific consent: Not Applicable; and
(ii) General consent: Applicable: each financial intermediary which (A) is authorised to make such offers under Directive 2014/65/EU, and (B) accepts such offer by publishing on its website the Acceptance Statement. |
| (c) Jurisdiction(s) where the offer may take place (together, the " Public Offer Jurisdictions(s) "): | The Netherlands |
| (d) Offer period for which use of the Base Prospectus is authorised by the Authorised Offeror(s): | The Offer Period (as specified in 5.2 (d) below) |
| (e) Other conditions for use of the Base Prospectus by the Authorised Offeror(s): | Not Applicable |

5.2. **Other terms and conditions of the offer**

- | | |
|--|--|
| (a) Offer Price: | The Issue Price |
| (b) Total amount of offer: | EUR 10'000'000 |
| (c) Conditions to which the offer is subject: | The offer of the Products is conditional on their issue. The Issuer reserves the right to withdraw the offer and/or to cancel the issue of the Products for any reason at any time on or prior to the Issue Date. The Issuer is not obliged to accept subscription applications and/or to issue subscribed Products. |
| (d) Time period, including any possible amendments, during which the offer will be open and description of the | An offer of the Products will be made from 25/02/2026 to, and including, 20/03/2029 (the " Offer Period "). The Offer Period may be discontinued at |

	application process:	any time. Notice of the early closure of the Offer Period will be made to investors through a notice published on the Notice Website.
(e)	Description of the application process:	Prospective investors may apply to the Authorised Offeror to subscribe for/order Products in accordance with the arrangements existing between the Authorised Offeror and its customers relating to the subscription/order of securities generally.
(f)	Details of the minimum and/or maximum amount of application:	The minimum amount of application which can be subscribed by the relevant investors is EUR 1'000. There is no maximum amount of application
(g)	Description of possibility to reduce subscriptions and manner for refunding excess amount paid by applicants:	Not Applicable
(h)	Details of method and time limits for paying up and delivering the Products:	Payments for the Products shall be made in accordance with the arrangements existing between the Authorised Offeror and its customers relating to the subscription/order of securities generally, as instructed by the Authorised Offeror.
(i)	Manner in and date on which results of the offer are to be made public:	Not Applicable
(j)	Whether tranche(s) have been reserved for certain countries:	Not Applicable
(k)	Process for notification to applicants of the amount allotted and indication whether dealing may begin before notification is made:	Not Applicable
(l)	Amount of any expenses and taxes specifically charged to the subscriber or purchaser:	Not Applicable
(m)	Product specific initial costs, Inducements:	Not Applicable
(n)	Name(s) and address(es), legal entity identifier, domicile, legal form and country of incorporation, to the extent known to the Issuer, of the placers in the various countries where the offer takes place:	Not Applicable
6.	BENCHMARK REGULATION:	Leonteq European Defense 12%RC Index is provided by Leonteq Securities AG. As of the date of these Final Terms, Leonteq Securities AG appears in the register of administrators and benchmarks established and maintained by ESMA pursuant to Article 36 of the Benchmark Regulation.

SUMMARY

INTRODUCTION AND WARNINGS

Warnings: The summary should be read as an introduction to the prospectus. Any decision to invest in the Products should be based on consideration of the prospectus as a whole by the investor. In certain circumstances, the investor could lose all or part of the invested capital. Where a claim relating to the information contained in the prospectus is brought before a court, the plaintiff investor might, under national law, have to bear the costs of translating the prospectus before the legal proceedings are initiated. Civil liability attaches only to those persons who have tabled the summary, including any translation thereof, but only where the summary is misleading, inaccurate or inconsistent when read together with the other parts of the prospectus or it does not provide, when read together with the other parts of the prospectus, key information in order to aid investors when considering whether to invest in the Products

You are about to purchase a product that is not simple and may be difficult to understand.

The Products: EUR 10'000'000 Outperformance Products with Participation due 27/03/2029 under the European Issuance and Offering Programme (ISIN: CH1484581991) the "**Products**" or the "**Securities**"

The Issuer: Leonteq Securities AG, acting through its Guernsey branch, Europaallee 39, 8004 Zurich, Switzerland, telephone number +41 58 800 1111. The Issuer's legal entity identifier (LEI) is: ML61HP3A4MKTTA1ZB671.

The Authorised Offeror(s): Each financial intermediary which is authorised to make such offers under Directive 2014/65/EU and accepts the Issuer's offer to grant consent to use the base prospectus in connection with the offer of the Products by publishing on its website a relevant statement of such acceptance.

Competent authority: The base prospectus was approved on 20 June 2025 by the Commission de Surveillance du Secteur Financier ("**CSSF**"), 283 route d'Arlon, L-1150 Luxembourg (Telephone number: +352 26 25 1 - 1).

KEY INFORMATION ON THE ISSUER

Who is the Issuer of the Securities?

Domicile and legal form of the Issuer, LEI, law under which the Issuer operates and country of incorporation: The Issuer was incorporated under Swiss law and registered in Zurich, Switzerland on 24 September 2007 as a stock corporation under article 620 et seq. of the Swiss Code of Obligations for an unlimited duration. As from that day, it is registered in the Commercial Register of the Canton of Zurich, Switzerland, under the number CHE-113.829.534 and operates under the laws of Switzerland. The registered office of Leonteq Securities AG is at Europaallee 39, 8004 Zurich, Switzerland. The Issuer's legal entity identifier (LEI) is: ML61HP3A4MKTTA1ZB671. The LEI of Leonteq Securities AG, Guernsey Branch is: 549300SCKU4B0LXWV721 and of Leonteq Securities AG, Amsterdam Branch is: 2549008UP5LW6G3XIW43.

Issuer's principal activities: The Issuer's main business activities include the development, structuring, distribution, hedging and settlement, lifecycle management and market-making of structured products, as well as the design and management of structured certificates and unit-linked life insurance policies. The Issuer provides some of these core services to platform partners under the terms of cooperation agreements. Additionally, the Issuer provides among others insurance and savings solution products as well as related services to third parties in Switzerland and abroad. The Issuer also distributes financial products to institutional investors and financial intermediaries who offer these products to retail investors.

Major shareholders, including whether it is directly or indirectly owned or controlled and by whom: The Issuer's share capital is held in its entirety by Leonteq AG, which as sole shareholder controls the Issuer.

Key managing directors: The current managing directors of the Issuer are: Christian Spieler (CEO), Hans Widler, Manish Patnaik, Reto Quadroni, Jasmin Koelbl-Vogt, Alessandro Ricci and Markus Schmid.

Statutory auditors: Deloitte AG has audited the financial statements of the Issuer for the financial years ended 31 December 2024 and 31 December 2023 and issued an unqualified opinion in each case.

What is the key financial information regarding the Issuer?

The following key financial information (according to IFRS) has been extracted from the audited financial statements of the Issuer for the financial year ended 31 December 2024.

Summary information – income statement		
	Year ended 31 December 2024 (audited)	Year ended 31 December 2023 (audited)
Selected income statement data		
Net profit (in CHF thousands)	10'081	23'455
Summary information – balance sheet		
	As at 31 December 2024 (unaudited)	As at 31 December 2023 (unaudited)
Net financial debt (financial liabilities minus financial assets) (in CHF thousands)	-365'171	-497'053
Summary information – cash flow		
	As at 31 December 2024 (audited)	As at 31 December 2023 (audited)
Net cash flows from operating activities (in CHF thousands)	-22'650	-346'142
Net cash flows from financing activities (in CHF thousands)	-37'729	-78'033
Net cash flows from investing activities (in CHF thousands)	-26'350	-26'753
Qualifications in audit report on historical financial information: There are no qualifications in the audit report of the Issuer on its historical financial information.		
What are the key risks that are specific to the Issuer?		
<p>The Issuer is subject to the following key risks:</p> <ul style="list-style-type: none"> • The Issuer is exposed to market risks arising from open positions in interest rate, currency, commodity, credit, equity and other products which arises primarily from the issuance of structured investment products and the related hedging activity. The realisation of such market risks may have a material adverse effect on the financial condition of the Issuer. • The Issuer's activities expose it to a variety of other risks including operational risk, credit risk of counterparties as well as market liquidity and liquidity and refinancing risk. These risks primarily arise through the issuance of structured investment products, the related investment of cash proceeds and the hedging of market risks through the purchase of derivative products. • The Issuer's business and financial condition may also be adversely affected by many factors, including in particular, the risk of (i) reduction in its credit rating, and (ii) its valuation and risk measurement model being incorrect or incorrectly used and its risk management measures not being adequate. 		
KEY INFORMATION ON THE PRODUCTS		
What are the main features of the Securities?		
<p>Type and class of Securities being offered and/or admitted to trading, including security identification numbers The Products are derivative securities in the form of certificates in uncertificated form. The Products are linked to a single underlying as described below. The Products will be cleared and settled through Euroclear Bank S.A./N.V. and/or Clearstream Banking S.A. and/or SIX SIS Ltd. Security identification numbers: ISIN: CH1484581991; Swiss Security Number: 148458199</p>		
<p>Currency, issue size and term of the Securities The currency of the Products will be Euro ("EUR") (the "Settlement Currency") The specified denomination per Product is: EUR 1'000.00 The notional amount is EUR 10'000'000.00 Redemption Date: 27/03/2029 This is the date on which the Products are scheduled to redeem. This date may be postponed following the postponement of a valuation date due to a disruption event.</p>		
<p>Rights attached to the Securities</p> <p>The Products will give each investor the right to receive a return, together with certain ancillary rights such as the right to receive notice of certain determinations and events. The return on the Products will depend on the performance of the</p>		

Underlying(s).

Redemption Amount :

Unless the Products have been previously redeemed or purchased and cancelled, the Issuer shall redeem the Products on the Redemption Date in accordance with the following:

- If the Final Fixing Level is at or above the Strike Barrier Level (such event a "**Strike Event**"), the Redemption Amount per Product will be determined in accordance with the following formula:

$$(CA \times PP) + (CA \times UPP \times \text{Final Return})$$

- Otherwise, the Redemption Amount per Product will be determined in accordance with the following formula:

$$\text{Calculation Amount} \times \text{Max}(\text{Final Performance}; 0)$$

In simple terms: The Redemption Amount will be the product of the Calculation Amount and the higher of (i) the Final Performance or (ii) zero.

Where:

- **CA or Calculation Amount:** EUR 1'000.00
- **Final Fixing Date:** in respect of the Underlying(s) 20/03/2029 subject to adjustment.
- **Final Fixing Level:** in respect of the Final Fixing Date and the Underlying, the Closing Index Level of the Underlying on the Final Fixing Date
- **Final Performance:** in respect of the Underlying, the percentage equal to (a) the Final Fixing Level of such Underlying divided by (b) the Initial Fixing Level of such Underlying.
- **Initial Fixing Date:** in respect of the Underlying, 20/03/2026, subject to adjustment.
- **PP or Protection Percentage:** 100.00 per cent.
- **UPP or Upside Participation Percentage:** 200.00 per cent.

<i>i</i>	<i>Underlying(s)</i>	<i>Index Sponsor</i>	<i>Bloomberg Ticker</i>	<i>Underlying Type</i>	<i>Initial Fixing Level (100.00%)</i>	<i>Strike Barrier Level (100.00%)*</i>
1	Leonteq European Defense 12%RC Index	Leonteq Securities AG	LEONED12	Index (<i>Proprietary Index</i>)	will be determined on the Initial Fixing Date	will be determined on the Initial Fixing Date

* Levels are expressed in percentage of the Initial Fixing Level

Governing law: The Products will be governed by Swiss law and the rights thereunder will be construed accordingly.

Status of the Products: The Products constitute general contractual obligations of the Issuer which are secured by collateral. The Products shall rank equally among themselves and, save for such exceptions as may be provided by applicable law, pari passu with all other collateralised and unsubordinated obligations of the Issuer.

Description of restrictions on free transferability of the Securities

The Products are offered and sold outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act and must comply with applicable transfer restrictions with respect to the United States. No offers, sales, resales or deliveries of the Products may be made in or from any jurisdiction and/or to any individual or entity except in circumstances which will result in compliance with any applicable laws and regulations and which will not impose any obligation on the Issuer and/or Leonteq Securities AG (the "**Lead Manager**"). Subject to the above, the Products will be freely transferable.

Where will the Securities be traded?

The Issuer and the Lead Manager do not assume any legal obligation in respect of the realisation of admission to trading as of any particular date or the maintenance of any admission to trading that is realised.

What are the key risks that are specific to the Securities?

The Products are subject to the following key risks:

- **Investors in the Products may lose up to the entire value of their investment in the Products, depending on the performance of the Underlying(s).**
- **Risks relating to certain features of the Products:**
 - The investor's ability to participate in any positive change in the value of the Underlying is limited, no matter how much the level, price or other value of the Underlying rises above the cap level over the life of the Products. Accordingly, the value of or return on the Products may be significantly less than if the investor had purchased the Underlying directly.

- The inclusion of a participation percentage in the Products means that the Products will be more speculative and riskier than in the absence of such feature, since smaller changes in the performance of the Underlying(s) can reduce (or increase) the return on the Products by more than if the Products did not contain a leverage feature. Investors should be aware that a small movement in the value of the Underlying(s) can have a significant effect on the value of the Products.
- **Risks relating to the Underlying(s):**
 - Past performance of the Underlying(s) is not indicative of future performance, and performance may be subject to unpredictable change over time;
 - Investors will not have any legal or beneficial rights of ownership in the Underlyings, and no claim against the index sponsor or any other third party in relation to the Underlyings; such parties have no obligation to act in investors' interests.
 - The market value of and the return on the Products depends on the performance of the Underlyings and its components and other macroeconomic factors. The index sponsor (and the Issuer of the Products) may be subject to regulatory changes regarding the publication and use of the Underlying(s) during the life of the Products which may negatively impact the performance of the Underlying(s). The Issuer and/or the Calculation Agent may adjust the terms of the Products in respect of the Underlying(s) referenced in order to comply with statutory requirements and such adjustments may affect the value and of return on the Products and may even result in the early redemption of the Products (the early redemption amount of which may be less than the initial investment amount or zero).
- **No or limited liquidity:** The Products may have no liquidity or the market for such Products may be limited and this may adversely impact their value or the ability of the Investor to dispose of them.
- **Secondary market price:** The market price of the Products prior to maturity may be significantly lower than their original purchase price. Consequently, if you sell your Products before their scheduled maturity (assuming you are able to), you may lose some of your original investment.
- **Early redemption:** The Products may be redeemed prior to their scheduled maturity in certain extraordinary circumstances. In such case, investors may only be able to reinvest the proceeds on less favourable market terms compared to when the Products were purchased.

KEY INFORMATION ON THE OFFER OF PRODUCTS TO THE PUBLIC AND/OR THE ADMISSION TO TRADING ON A REGULATED MARKET

Under which conditions and timetable can I invest in this Security?

Terms and conditions of the offer

Issue Date: 27/03/2026

The issue price on the Issue Date: 96.5 % of the Specified Denomination (no distribution fees)

The Products are offered for subscription in the Netherlands during the period from (and including) 25/02/2026 to (and including) the Final Fixing Date.

The Products are offered subject to the following conditions:

- The offer of the Products is conditional on their issue.
- The Issuer reserves the right to withdraw the offer and/or to cancel the issue of the Products for any reason at any time on or prior to the Issue Date.
- The Issuer is not obliged to accept subscription applications and/or to issue subscribed Products.

Description of the application process: Prospective investors may apply to the Authorised Offeror(s) to subscribe for/order Products in accordance with the arrangements existing between the Authorised Offeror(s) and its customers relating to the subscription/order of securities generally.

Details of the minimum and/or maximum amount of application: The minimum amount of application which can be subscribed by the relevant investor equals the Specified Denomination. There is no maximum amount of application.

Details of method and time limits for paying up and delivering the Products: Payments for the Products shall be made in accordance with the arrangements existing between the Authorised Offeror(s) and its customers relating to the subscription/order of securities generally, as instructed by the Authorised Offeror(s).

Estimated expenses or taxes charged to investor by issuer/offeror

Information about expenses additional to the Issue Price or the purchase price can be obtained from the relevant distributor. There are no estimated expenses or taxes charged to the investor by the Issuer.

Who is the offeror and/or the person asking for admission to trading?

The Authorised Offeror(s) of the Products shall be each financial intermediary which is authorised to make such offers under Directive 2014/65/EU and accepts the Issuer's offer to grant consent to use the Base Prospectus in connection with the offer of the Products by publishing on its website a relevant statement of such acceptance.

Why is the Prospectus being produced?

Use and estimated net amount of proceeds

The proceeds from the sale of the Products are used for hedging the payment obligations arising from the issue of the Products and for the purposes of the Issuer's ordinary business activities.
The estimated net proceeds are 100 per cent. of the Issue Size.

Underwriting agreement on a firm commitment basis: The offer of the Products is not subject to an underwriting agreement on a firm commitment basis.

Description of the most material conflicts of interest pertaining to the offer or the admission to trading

The Issuer and its subsidiaries, the Lead Manager and the Calculation Agent deal in and hold interests in the Underlying(s) or in components of the Underlying(s) or in options or futures contracts relating to the Underlying(s) or components thereof in their normal course of business and from time to time may participate in transactions connected to the Products for their own account or on behalf of others. Furthermore, Issuer and its subsidiaries may exercise another function in relation to the Products or Underlying(s) or components thereof, such as issuing agent, calculation agent, paying agent and/or administrative agent. The Issuer and its subsidiaries, the Lead Manager and the Calculation Agent can also receive non-public information regarding the Underlying(s) or components of the Underlying(s), but are not obliged to pass such information on to the investors. The Issuer can involve cooperation partners and external advisors in the issuance of Products, e.g., in the composition and adjustment of a basket or index. It is possible that such cooperation partners and advisors may pursue their own interests in the course of an issuance by the Issuer and when providing their associated advice.

The selling price of the Products, where appropriate in addition to fixed issue surcharges, management fees, performance fees or other fees, may contain surcharges on the initial mathematical 'fair' value of the Products (the "**margin**"). This margin will be determined by the Issuer in its reasonable discretion and can differ from surcharges that other issuers impose on comparable products. This margin covers, among other things, the costs of structuring, market making and settlement of the Products and also includes the expected profit for the Issuer.